Oculis Holding AG
OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.31
Price+0.89%
$0.10
1Y
Price
Market Cap
$646.587m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in CHF.-6785.0%
EBITDA Margin-6936.2%
Net Profit Margin-5572.8%
Free Cash Flow Margin-6785.0%
EBITDA Margin-6936.2%
Net Profit Margin-5572.8%
Free Cash Flow MarginRevenue
$504k
-26.5%
1y CAGR-8.8%
3y CAGR-6.6%
5y CAGREarnings
-$95.061m
-21.4%
1y CAGR-49.1%
3y CAGR-64.0%
5y CAGREPS
-$1.73
-3.3%
1y CAGR-42.1%
3y CAGR-58.3%
5y CAGRBook Value
$196.061m
$243.264m
Assets$47.204m
Liabilities$2.241m
DebtDebt to Assets
0.9%
-
Debt to EBITDAFree Cash Flow
-$63.172m
-28.6%
1y CAGR-35.2%
3y CAGR-53.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company